Your insurance denied Mounjaro. Here is how to appeal it.

Why Mounjaro gets denied

Mounjaro (tirzepatide) received FDA approval in May 2022 for glycemic control in adults with type 2 diabetes. It is the first approved dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist, a distinct mechanism from prior GLP-1 medications like semaglutide. The SURPASS trial series documented some of the most significant HbA1c reductions recorded in a type 2 diabetes medication program at the time of approval. It is also different from Zepbound: both are tirzepatide from Eli Lilly, but Mounjaro is approved for type 2 diabetes, while Zepbound (approved November 2023) is approved for obesity and chronic weight management. An appeal for Mounjaro must cite the correct product and indication, using the wrong one creates a preventable denial. The denials cluster into a handful of patterns:

• Step therapy, document prior agents first. Most plans require documented failure of or intolerance to metformin, and sometimes a sulfonylurea or another preferred agent, before approving Mounjaro. If the prior authorization did not include this history, even if you have clearly tried these medications, the plan triggers a step-therapy denial.
• Prior authorization not filed or lapsed. Mounjaro universally requires prior authorization. A PA that expired at plan renewal, a PA not submitted before the prescription was filled, or a PA missing supporting documentation (HbA1c values, type 2 diabetes diagnosis) generates an automatic, purely administrative denial.
• Type 2 diabetes not documented to the plan's exact standard. Plans may require explicit HbA1c above a specific threshold, ICD-10 E11.x diagnosis coding, or documentation that lifestyle modifications were attempted. Missing any of these from the prior authorization can trigger denial even when the diagnosis is not in clinical question.
• Mounjaro vs. Zepbound confusion, including off-label weight loss. Mounjaro and Zepbound are both tirzepatide but have different FDA indications. If a prior authorization included a weight-management indication for Mounjaro (which is not its approved use), or the plan applies Zepbound's formulary status to Mounjaro, the denial may be a coding error separate from any clinical question. The clean appeal is grounded in the type 2 diabetes indication.
• Non-preferred formulary tier. Plans may cover Mounjaro but place it in a specialty or non-preferred tier with higher cost-sharing. A formulary exception request supported by documentation that preferred alternatives are clinically inadequate, or that you have already tried them, can address tier restrictions.
• 2025 step-therapy policy changes. Several major insurers, including UnitedHealthcare, implemented new step-therapy requirements for GLP-1 and dual-agonist medications in 2025, requiring additional prior-treatment documentation. If you were previously approved and are now denied at renewal, the policy change, not a change in your clinical situation, may be the cause. Appeals addressing the specific policy-change language have a clear factual basis.

How to appeal it

The pattern that wins is precision: make the medical reviewer's job a simple checkbox match against the plan's own criteria. For Mounjaro, the single most important guardrail is citing the correct product, Mounjaro for type 2 diabetes, not Zepbound, and the type 2 diabetes indication throughout.

Sources include your plan's published GLP-1 or GIP/GLP-1 coverage policy and the Mounjaro prescribing information. We cite the specific policy that applies to your plan when we build your appeal.

Mounjaro denial: common questions